“Chronic obstructive pulmonary disease and phenotypes: a state-of-the-art.”

Corlăteanu, Alexandru; Mendez, Yamely; Wang, Ya-Feng; Garnica, Ricardo de Jesus Avendaño; Botnaru, Victor; Siafakas, Nikolaos M.

doi:10.1016/j.pulmoe.2019.10.006

Cited by 73 publications

(47 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Systemic manifestations in COPD are diverse and affect patients differently, making them a heterogeneous population, 43 in which individuals are distinguished in relation to biological, clinical, and functional characteristics. 44 In an attempt to identify subgroups of patients, in order to act more precisely, the correlation of biomarkers with clinical and functional characteristics of patients with stable COPD has been explored. However, studies that investigated inflammatory biomarkers using plasma analysis and clinical characteristics such as sex, 18 dyspnea, 17 fatigue, 17 pain, 17 and exacerbation risk 19 found no associations between these variables.…”

mentioning

confidence: 99%

Systemic Cytokine Profiles of CD4+ T Lymphocytes Correlate with Clinical Features and Functional Status in Stable COPD

Uzeloto

Toledo-Arruda

Silva

et al. 2020

COPD

View full text Add to dashboard Cite

mentioning

confidence: 99%

Systemic Cytokine Profiles of CD4+ T Lymphocytes Correlate with Clinical Features and Functional Status in Stable COPD

Uzeloto

Toledo-Arruda

Silva

et al. 2020

COPD

View full text Add to dashboard Cite

“…Тому важливою проблемою сучасної медицини стає групування хворих для виробки засад раціонального лікування, для чого використовується фенотипування [1], тобто виділення основних варіантів на підставі клінічних та лабораторних характеристик [2,3,4]. У 2020 р. науковці почали виступати за включення фенотипів у міжнародні керівництва з ведення ХОЗЛ [5].…”

Section: львівський національний медичний університет імені данила галицького українаunclassified

“…Першу спробу фенотипувати ХОЗЛ зробив G. L. Snider у 1989 р. і його підхід використало Американське торакальне товариство у рекомендаціях 1995 р. [5]. Практичного застосування набуло виділення двох фенотипів ХОЗЛ: А (хронічний бронхіт, запальний характер, часті загострення, системні маніфестації та коморбідності) та В (емфізема, легенева гіперінфляція без частих загострень) [4,5].…”

Section: львівський національний медичний університет імені данила галицького українаunclassified

“…Практичного застосування набуло виділення двох фенотипів ХОЗЛ: А (хронічний бронхіт, запальний характер, часті загострення, системні маніфестації та коморбідності) та В (емфізема, легенева гіперінфляція без частих загострень) [4,5]. За іншими системами у якості критеріїв поділу на фенотипи запропоновано використовувати клінічні (вік пацієнта на початок хвороби, стать, куріння, наявність чи відсутність ожиріння чи кардіоваскулярних хвороб, анемії) чи патофізіологічні (еозинофільне, нейтрофільне, імунне запалення) ознаки та відповідь на лікування (добра чи рефрактерність, застосування кортикостероїдів) [3,4,5,6]. Ці критерії використовуються ізольовано або у довільних комбінаціях, що дотепер не дозволяє застосовувати їх на практиці.…”

Section: львівський національний медичний університет імені данила галицького українаunclassified

See 1 more Smart Citation

Clinical and Pathophysiological Phenotyping of Chronic Obstructive Pulmonary Disease

Radchenko¹,

Fedуk²

2021

Ukr. ž. med. bìol. sportu

View full text Add to dashboard Cite

The purpose of the study was to determine the clinical and laboratory features of inflammatory phenotypes among patients with chronic obstructive pulmonary disease, moderate respiratory failure and anemia of chronic disease. Materials and methods. The study included 150 patients with exacerbation of chronic obstructive pulmonary disease and chronic anemia, in which inflammatory phenotypes were identified, among which the largest share was neutrophilic (66/44.0±4.0%), less lymphocytic (35/23.3±3.4%) and eosinophilic (16/10.7±2.5%). In 33/22.0% of patients, the inflammatory phenotype was mixed and patients were excluded from the study. Among 117 patients included in the study, 67.5% were men and 32.5% were middle-aged (25.6%), elderly (42.7%) and senile (24.8%). The results were processed by the methods of variation statistics, the materiality threshold p <0.05. Results and discussion. It was established, that peripheral blood analysis and biochemical parameters, regardless of the pathophysiological nature of inflammation in all groups showed moderate dysfunction of external respiration, normochromic normocytic nature of mild chronic anemia with activation of all components of the external coagulation mechanism and increased prothrombin time and inflammation activation (by C-reactive protein and seromucoids). The neutrophilic phenotype of inflammation, in comparison with lymphocytic and eosinophilic, was the most common and was accompanied by the most pronounced anemic syndrome, the highest activity of systemic inflammation and the most pronounced syndrome of endogenous intoxication with deterioration of liver function. The lymphocytic phenotype of inflammation was the second widespread and was characterized by the most pronounced normochromic anemic syndrome with the most pronounced predisposition to hypercoagulation (the highest prothrombin index) with high activity of the inflammatory syndrome. The eosinophilic phenotype of inflammation was significantly less common than the neutrophilic and lymphocytic with the favorable characteristics of the anemic syndrome and with low inflammatory activity and the small activity of endogenous intoxication but the highest fasting blood glucose level as normo-hyperglycemia. Conclusion. Clinical and pathophysiological phenotyping of chronic obstructive pulmonary disease makes it possible to determine not only the activity of inflammation, but also the severity of anemic syndrome, endogenous intoxication, liver status and carbohydrate metabolism, which is of practical importance for both physicians and scientists

show abstract

“…1 More recently, work has focused on developing therapies specific to clinical COPD phenotypes by utilizing ULABAs in combination with other types of respiratory medications, including muscarinic antagonists and inhaled corticosteroids. 9,10 Additionally, new and innovative delivery systems are being developed to optimize drug delivery to the lungs and improve ease of use. 11,12 This review will focus on translational and clinical studies that are helping to create a patient-centered approach to COPD treatment.…”

Section: Introductionmentioning

confidence: 99%

Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease

Burkes¹,

Panos²

2020

JEP

View full text Add to dashboard Cite

Introduction Inhaled β-agonists have been foundational medications for maintenance COPD management for decades. Through activation of cyclic adenosine monophosphate pathways, these agents relax airway smooth muscle and improve expiratory airflow by relieving bronchospasm and alleviating air trapping and dynamic hyperinflation improving breathlessness, exertional capabilities, and quality of life. β-agonist drug development has discovered drugs with increasing longer durations of action: short acting (SABA) (4–6 h), long acting (LABA) (6–12 h), and ultra-long acting (ULABA) (24 h). Three ULABAs, indacaterol, olodaterol, and vilanterol, are approved for clinical treatment of COPD. Purpose This article reviews both clinically approved ULABAs and ULABAs in development. Conclusion Indacaterol and olodaterol were originally approved for clinical use as monotherapies for COPD. Vilanterol is the first ULABA to be approved only in combination with other respiratory medications. Although there are many other ULABA’s in various stages of development, most clinical testing of these novel agents is suspended or proceeding slowly. The three approved ULABAs are being combined with antimuscarinic agents and corticosteroids as dual and triple agent treatments that are being tested for clinical use and efficacy. Increasingly, these clinical trials are using specific COPD clinical characteristics to define study populations and to begin to develop therapies that are trait-specific.

show abstract

“Chronic obstructive pulmonary disease and phenotypes: a state-of-the-art.”

Cited by 73 publications

References 38 publications

<p>Systemic Cytokine Profiles of CD4+ T Lymphocytes Correlate with Clinical Features and Functional Status in Stable COPD</p>

<p>Systemic Cytokine Profiles of CD4+ T Lymphocytes Correlate with Clinical Features and Functional Status in Stable COPD</p>

Clinical and Pathophysiological Phenotyping of Chronic Obstructive Pulmonary Disease

<p>Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease</p>

Contact Info

Product

Resources

About